4,901 trials
Healthy
Primary: Percentage of Participants With Treatment-emergent Drug-related Adverse Events (AEs) — 4.5; 0; 22.2; 0 percentage of participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point — NA; NA nanomol (nmol) * hours (h) /…
Healthy
Primary: SRD and MD Part: Number of Participants With Drug-related Adverse Events (AEs) — 1; 2; 1; 0 Participants
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 0; 12.5; 25.0; 37.5 Percentage of participants
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 0; 0; 1 Participants
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 12.5; 0.0; 16.7; 0.0 Percentage of participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab — 215; 214; 293; 695 Microgram*…
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib — 18927; 23158 hours* nanograms per milliliter(h*ng/mL)
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab — 14.3; 15.2 micrograms/milliliter (µg/mL)
Healthy
Primary: Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3074828 — 14.4; 21.1 microgram per milliliters (μg/mL)
Pulmonary Disease, Chronic Obstructive
Primary: Part A, Cohort-1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 6 Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3074828 — 9.19; 8.19 microgram/milliliter (ug/mL)
Pain
Primary: The Area Under the Plasma Concentration [AUC] Versus Time Curve Calculated From Time Zero to the Last Measurable Sampling Time Point (Tlast) (AUC [0-tlast]) — 47.18…
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 17.8; 13.4; 12.7 microgram per milliliter (mcg/mL)
Hepatic Impairment · Healthy Participants
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06835919 — 14090; 13090; 18930; 19630 nanogram*hour per…